- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 327 Pages
Global
From €2662EUR$2,800USD£2,236GBP
€3803EUR$4,000USD£3,195GBP
- Report
- September 2024
- 135 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- February 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2024
- 210 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- July 2024
- 142 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- February 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- April 2024
- 121 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- September 2024
- 250 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- July 2024
- 156 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- March 2024
- 102 Pages
Global
From €808EUR$850USD£679GBP
€1616EUR$1,700USD£1,358GBP
- Report
- May 2022
- 228 Pages
Global
From €2495EUR$2,625USD£2,096GBP
€4991EUR$5,250USD£4,193GBP
- Report
- April 2022
- 307 Pages
Global
From €5276EUR$5,550USD£4,432GBP
- Report
- February 2022
- 97 Pages
Global
From €903EUR$950USD£759GBP
- Report
- February 2023
- 144 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- July 2023
- 147 Pages
Global
From €2139EUR$2,250USD£1,797GBP
- Report
- March 2021
- 64 Pages
India

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more